Status:

UNKNOWN

Nebulised Heparin in Patients With COVID-19 Pneumonia

Lead Sponsor:

Lady Reading Hospital, Pakistan

Conditions:

COVID-19 Pneumonia

Eligibility:

All Genders

18+ years

Phase:

PHASE2

PHASE3

Brief Summary

While the pandemic continues to incite panic and the guideline recommendations regarding management of COVID continue to change, we have growing evidence that ARDS secondary to Covid-19 is associated ...

Detailed Description

Second-year into the deadly COVID-19 pandemic and humanity continues to get affected/infected. The world has seen a total cases of 99.7 M, a death toll of 2.14 M, and counting4. To date, Pakistan has ...

Eligibility Criteria

Inclusion

  • Age 18 year or older.
  • Either gender
  • Currently admitted to hospital.
  • There is a PCR-positive sample for SARS-CoV-2 within the past 21 days. The sample can be a nasal or pharyngeal swab, sputum, tracheal aspirate, Broncho alveolar lavage, or another sample from the Patient
  • WHO Modified ordinal clinical scale 3-5

Exclusion

  • Intubated and on mechanical ventilation, or requiring immediate intubation as per the treating clinician's assessment
  • Heparin allergy or heparin-induced thrombocytopenia
  • APTT \>120 s, not due to anticoagulant therapy and does not correct with the administration of fresh frozen plasma
  • Platelet count \<20 × 109 /L
  • Pulmonary bleeding or uncontrolled bleeding
  • Pregnant or might be pregnant
  • Acute brain injury that may result in long-term disability
  • Myopathy, spinal cord injury, or nerve injury or disease with a likely prolonged incapacity to breathe independently e.g. Guillain-Barre syndrome
  • Treatment limitations in place (Ceiling of care), i.e. not for intubation, not for ICU admission
  • Death is imminent or inevitable within 24 h
  • Clinician objection
  • Refusal to consent

Key Trial Info

Start Date :

June 20 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 20 2022

Estimated Enrollment :

180 Patients enrolled

Trial Details

Trial ID

NCT05255848

Start Date

June 20 2022

End Date

October 20 2022

Last Update

April 26 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Pulmonology Department, Lady Reading Hospital, Peshawar

Peshawar, Khyber Pakhtunkhwa, Pakistan, 25000